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Abstract 
 
Background: Hand eczema is a common and distressing condition with multiple causes such as atopy, irritant 
and allergic contact dermatitis. Fumaria parviflora, is known as Shahtareh in Persian, is a folk medicine for ec-
zema. This study aimed to evaluate the effect of alcoholic extract of Fumaria parviflora on hand eczema.  
 
Methods: In a randomized double-blind, placebo-controlled study, 44 patients with hand eczema were randomly 
assigned to apply 4% cream of Fumaria parviflora or vehicle cream to hand twice daily for 4 weeks. 
 
Results: The reduction of eczema area and severity index score before and two weeks after therapy was statis-
tically significant between vehicle treated and in treated group. Only one patient showed side effects such as 
erythema and population. 
 
Conclusion: Fumaria parviflora appears to be tolerated by most patients and the findings showed that its extract 
may be considered as an effective agent for treatment of chronic hand eczema. 
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Introduction 
 
Hand eczema is a common and distressing condition, 
and poses such difficult problems for dermatologists 
that it deserves separate condition.
1 Patients with hand 
eczema have multiple causes for their dermatitis such 
as atopic and irritant or allergic contact dermatitis. 
Hand eczema represents a major occupational problem 
and accounts for more than 80% of all occupational 
dermatitis. Hair dressers, food service workers and 
health care workers are particularly affected. Both wet 
and low humidity conditions are risk factors for hand 
dermatitis. Hard water also increases the incidence of 
hand dermatitis. Other forms of hand eczema are acute 
vesiculobullous (pompholyx), chronic vesiculobullous 
and hyperkeratotic forms.
2 Minor degrees of hand ec-
zema are very common and virtually everyone suffers 
from mild dryness and chapping at sometime. In most 
surveys, hand eczema is approximately twice more 
common in females.
1 Fumaria parviflora L. is known 
as Shahtareh in Iran. Aqua distillate of aerial parts of 
Fumaria parviflora (Aragh-e-Shatareh) is used very 
frequently in different parts of Iran, and is a Persian 
folk medicine. The aerial parts of plant have been con-
sidered to be diuretic, hepatoprotective, laxative, blood 
purifier and used in liquid form for treatment of sca-
bies, eczema, acne and other skin disorders, external-
ly.
3,4 The present study was undertaken to find out the 
efficacy of topical cream of the alcoholic extract of this 
plant on hand eczema. 
 
 
Materials and Methods 
 
This randomized double-blind (patient-physician), 
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placebo-controlled study assessed the efficacy of al-
coholic extract of Fumaria parviflora (FP) on hand 
eczema. Randomization was conducted based on 
block randomization design.  
Flowering aerial parts of FP was collected during 
April 2008 from rural areas around Shiraz, Fars Prov-
ince, south of Iran, and it was authenticated by a well-
known professor at Botany Department of the Faculty 
of Science of Shiraz University. The plant was dried 
at the room temperature. Fifty grams of dried plant 
powder were macerated in 80% aqueous ethanol (100 
ml) at room temperature for 48 hours. The extract 
was filtered and concentrated under reduced pressure 
and low temperature (40˚C) on a rotary evaporator to 
dry. The extract yield was 36 mg/gr of dried plant. 
Total polyphenols were determined by the Folin–
Ciocalteu procedure.
5 Aliquots (0.1 ml) of test-
solution were transferred into the test tubes and vol-
umes brought up to 0.5 ml by water. After addition of 
0.25 ml Folin–Ciocalteu reagent and 1.25 ml 20% 
aqueous Na2CO3 solution, tubes were vortexed and 
absorbance of blue-colored mixtures was recorded 
after 40 min at 725 nm against blank, containing 0.1 
ml of extraction solvent. The amount of total poly-
phenols was calculated from the calibration curve of 
routine standard solutions, covering the concentration 
range between 0.1 and 1.0 mg/ml, and expressed as % 
(w/w), with regards to dry plant material weight. 
Stearic acid, paraffin, glycerin, cetyl alcohol, potassi-
um hydroxide, methyl and propyl paraben were used 
in preparation of 4% FP cream. All of them were of 
pharmaceutical grade. The stability of the cream was 
assessed for 3 months.  
This study was conducted in autumn 2009, in Sha-
hid Faghihi Skin Clinic attendants, affiliated to Shiraz 
University of Medical Sciences. Patients were as-
signed to apply 4% cream of FP or vehicle cream to 
hands based on block randomization design. Written 
informed consent was obtained from each patient be-
fore initiating study procedures. Healthy patients with 
hand eczema that did not use topical medication in 2 
weeks ago or systemic medication in one month ago 
were enrolled. Patients were also excluded if they 
were pregnant or had lactation, or hypersensitivity to 
test medication which revealed clinically. Patients 
applied the cream (drug or placebo) to treatment area 
twice daily for 4 weeks. Efficacy assessments were 
performed at baseline and two weeks after termina-
tion of therapy, according to eczema area and severity 
index (EASI)
6 (Table 1). A total of 44 patients com-
pleted the study. One patient in drug group developed 
side effect in form of erythema and population after 
two weeks of therapy that treatment stopped and the 
patient was excluded from study. Both dermatologist 
and patients were blind to study groups. Data were 
recorded by an assessor. Variables were erythema, 
population, excoriation and lichenification rating each 
on a scale of 0 (none) to 1 (mild), 2 (moderate), 3 
(severe). Demographic and baseline data were sum-
marized for all patients who were matched complete-
ly. This clinical trial was registered in the website of 
Ministry of Health and Medical Education clinical 
trial center (IRCT, CT-84-2759; 
IRCT138810303074N1). 
 
Table 1: EASI score
Body region
a EASI 
Head and Neck (H)  (E+I+Ex+L)
b×area score×0.1 
Upper limbs (U.L)  (E+I+Ex+L)×area score×0.2 
Trunk (T)  (E+I+Ex+L)×area score×0.3 
Lower Limbs (LL) (E+I+Ex+L)×area score×0.4
EASI   Sum
c of the above 4 body 
region scores 
aFor children aged 0-7 years, proportionate area 
were: head & neck 20%, upper limbs 20%, trunk 
30%, lower limbs 30%; 
bE: erythema score, I: indura-
tions, population score, Ex: excoriation score, L: li-
chenification score; 
cWhere area is defined on a 7- 
point ordinal scale: 0: no eruption, 1: <10%, 2: 10%-
29%, 3: 30%-49%, 4: 50%-69%, 5: 70%-89%, 6: 
90%-100%.  
 
The results were shown as mean±standard devia-
tion (SD). For data analysis, SPSS software (Version 
13, Chcago, IL, USA) was used and statistical analy-
sis was performed by paired T-test and independent 
T-test. All statistical comparisons were based on a 
significant level of p<0.05. 
 
 
Results 
 
The patient average age was 33.3 years with a range 
of 13 to 58 years and the majority were female   
(Table 2). Duration of disease was 46 months in the 
case and 41 months in the control groups. The reduc-
tion of EASI score that was determined by Paired T-
test, was statistically significant in placebo group (p-
value=0.03). Mean score was 4.3±1.1 before therapy 
and 3.6±1.6 after therapy (Figure 1). The reduction of 
EASI score in treated group was statistically signifi-
cant (p-value≤0.001). Mean score was 4.6±1.5 before 
and 3.1±1.3 after therapy (Figure 2). By use of   Jowkar et al. 
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independent T-test, statistically significant improve-
ment was observed in EASI score in treated group 
compared with the placebo group (p value=0.03, 
mean difference of -0.82, t of -2.22) (Figure 3). 
The amount of total polyphenols of our plant was 
15 mg (routine equivalents) with regards to 100 gr 
dry plant material weight.  
 
 
Discussion 
 
Super-potent and potent topical steroid agents are first 
line pharmacological therapies for hand eczema but 
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Fig. 1: The comparison of clinical manifestation in placebo group before and 2 weeks after treatment. Values are 
mean+SD. 
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Fig. 2: The comparison of clinical manifestation in drug group before and 2 weeks after treatment. Values are 
mean+SD. 
 
Table 2: Patient demographic and baseline charac-
teristic. 
N=44 
Sex, No. (%)
Male 14 (31.8) 
Female 30 (68.2) 
Age, Year
Mean 33.3 
Range 13-58 
Type of eczema, No. (%) 
32 ( 72.7 ) irritant contact dermatitis 
8 ( 18.4 ) atopic dermatitis 
3 ( 6.8 ) allergic contact dermatitis 
1 ( 2.2 ) pompholyx Fumaria parviflora in eczema 
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chronic use of potent fluorinated corticosteroids may 
be associated with skin atrophy.
2 
Plants are widely used against skin disorders in 
traditional medicine. Fumaria parviflora plant has 
been used in the treatment of eczema in the Persian 
folk medicine. Seven species of the annual plants of 
genus  Fumaria grow in Iran. Fumaria officinalis 
(FO) is the medicinal species, which is used as a cho-
lagogue. FO (fumitory or earth smoke) is not found in 
Iran but FP is used instead, in folk medicine. FO is a 
medicinal plant which has had a role in empirical 
medicine in numerous countries and has favorable 
effects on skin complaints.
7 We found no previous 
reports on the effect of Fumaria on eczema, although 
the antipsoriasis properties of Fumaric acid, one of 
constituents of Fumitory, have been described.
8 An-
other study showed the organic and phenolic acids 
identified in eight Fumaria species have been used for 
many centuries in folk medicine. The results of this 
chemotaxonomic investigation showed that the content 
of Fomaric acid in FP and FO was similar.
9 
Fumaric acid content of FP (from south of Iran) 
has been determined to be about 0.93% w/w.
10 FP 
also has fumaric acid esters (FAEs). The effective-
ness and safety of FAEs for the treatment of psoriasis 
has been demonstrated.
11,12 Their mode of action 
however is poorly understood. FAEs should be con-
sidered as drugs showing considerable immunosup-
pressive efficacy.
10 Mono methylfumarate (MMF) is 
believed to be the most bioactive metabolite of 
FAEs.
13 The beneficial effects of FAEs medication 
are accompanied by a down regulation of type І cyto-
kines production by T-helper lymphocytes.
13 There-
fore, decreased production of IFN-gamma
14 MMF 
interfered with monocyte-derived dendritic cells 
(DCs) differentiation, resulting in impaired matura-
tion of these cells. MMF-incubated iDCs could be 
maturated by lipopolysaccharide (Lps), these lps-
stimulated cells (MMF-DCs) displayed low expres-
sion of molecules important for establishing contact 
with T lymphocytes, therefore MMF-DCs are poor 
activators of T cells.
13 It has been demonstrated that 
FAEs have immunomodulatory effects, including in-
hibition of T lymphocyte proliferation
15,16 as well as 
inhibition of pro-inflammatory granulocyte cytokines 
and modulation of monocyte cytokine production. 
Dimethylfumarate, the main ingredient of FAEs, is a 
potent inducer of apoptosis in T lymphocyte.
15 FAEs 
are potential therapy for patients with recalcitrant 
granulomatous skin disorders and therefore, may be 
mediated by similar immunomodulatory mechanisms 
as in psoriasis.
16 In the other way, the interaction of 
trigger factors, keratinocytes and T lymphocytes, 
seems particularly important in eczema, mostly. In 
allergic contact dermatitis interaction with the anti-
gen-bearing dendritic cells causes T-lymphocytes dif-
ferentiation (Th1, Th2) and secreting different pattern 
of cytokines. Also, in irritant contact dermatitis, the 
release of inflammatory mediators and cytokines are 
involved.
1 Therefore, one of the reasons for treatment 
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Fig. 3: The comparison of disease severity according to EASI score in case and control group two weeks after 
treatment. Values are mean+SD [*: Significantly different from control group (p<0.05)]. 
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of hand eczema by FP is existence of FAEs, but other 
active ingredients must be found in future studies. 
Regarding other investigations, the biological activ-
ity of Fumaria species is mostly associated with the 
presence of isoquinoline alkaloids. It might be tempt-
ing to speculate that the Fumaria extract has beneficial 
effect as synthetic fumaric acid esters because possibly 
the combination of different compound is responsible 
for the pharmacological effects.
17 
In this study, the results showed that alcoholic FP 
extract produced improvement in all types of hand 
eczema in comparison to placebo. In conclusion, the 
obtained results confirm the presence of immono-
modulatory principles in FP, giving a rational support 
to their use by traditional medicine. 
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